Prothrombin complex concentrate (PCC) vs. non-PCC strategies for warfarin reversal in left ventricular assist device recipients: A systematic review and meta-analysis.
Chavada Piyabun-Yanon, Nattawut Leelakanok, Bundarika Suwanawiboon et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated prothrombin complex concentrate (PCC) versus non-PCC strategies for warfarin reversal in left ventricular assist device (LVAD) recipients. Involving 779 patients across 18 studies, the analysis found that PCC led to faster INR correction (mean difference -7.6 hours) and required fewer FFP units (-2.6 units) compared to non-PCC strategies, with no significant differences in mortality or thrombotic events.
Key findings
- PCC resulted in faster INR correction than non-PCC strategies (mean difference -7.6 hours).
- PCC required fewer FFP units compared to non-PCC strategies (-2.6 units).
- Mortality rates were 24.0% for PCC and 15.8% for non-PCC strategies.
- Thrombotic events occurred in 16.5% of PCC recipients versus 12.1% in non-PCC recipients.
Why it matters
Understanding the effectiveness and safety of PCC versus non-PCC strategies for warfarin reversal in LVAD patients is crucial for managing bleeding complications and optimizing patient outcomes in critical care settings.